Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590513 | 0.83 | CSNK1D (0.41) | FLT3EGFRPTGS2KIF18ACSNK1D | |
| SCHEMBL1590512 | 0.83 | CSNK1D (0.41) | FLT3EGFRPTGS2KIF18ACSNK1D | |
| SCHEMBL4438500 | 0.78 | CSNK1D (0.44) | FLT3EGFRCSNK1DCSNK1ESRC | |
| SCHEMBL12703837 | 0.78 | FLT3 (0.62) | FLT3KIF18AABL1 | |
| SCHEMBL1591536 | 0.76 | EGFR (0.41) | FLT3EGFRCSNK1DCSNK1ESRC | |
| SCHEMBL1591535 | 0.76 | EGFR (0.41) | FLT3EGFRCSNK1DCSNK1ESRC | |
| SCHEMBL12703940 | 0.76 | SRC (0.45) | EGFRPTGS2KIF18ASRCABL1 | |
| SCHEMBL4443143 | 0.76 | CSNK1D (0.43) | FLT3EGFRCSNK1DCSNK1ESRC | |
| SCHEMBL3589147 | 0.74 | CSNK1D (0.46) | CSNK1DCSNK1E | |
| SCHEMBL1591775 | 0.74 | CSNK1D (0.42) | FLT3EGFRPTGS2CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | claimed |
| EP-1656378-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF RECEPTOR TYROSINE KINASE ACTIVITY | IRM LLC (BM) | 2006-05-17 | — | — | EP | claimed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | claimed |
| WO-2005016528-A2 | 6-SUBSTITUTED ANILINO PURINES AS RTK INHIBITORS | IRM LLC (BM) | 2005-02-24 | — | — | WO | claimed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | FLT3 5/4885EGFR 38/4885PTGS2 4090/4885 |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | FLT3 317/4885EGFR 4362/4885PTGS2 1147/4885 |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | BMX, LCK, FYN | FLT3 5/4885EGFR 38/4885PTGS2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.